Special FocuS: oncology
Head and neck carcinoma is the sixth most common cancer worldwide, encompassing epi thelial carcinomas and squamous cell carcino mas charac terized by their pathological charac teristics [1] . Cancer in the head and neck region can arise from soft tissues, bones and a variety of glands in the upper aerodigestive tracts, including the oral cavity, oropharynx, hypopharynx, lar ynx, nasopharynx, paranasal sinuses and salivary glands [2] . Approximately 60,000 Americans are diagnosed with head and neck cancer each year. It has been noted, according to statistics, that the largest of all these is head and neck squamous cell carcinoma (HNSCC) , where malignancies originate in the most superficial layer of tissues or organs in the head and neck region. Earlystage (stage I and II) local HNSCC has good disease prognosis and local tumor control, yielding a stable survival rate of approximately 81% in the past decade. By contrast, patients with regional or metastatic disease have a poor survival rate (as low as 52 and 26%, respectively) and this has improved little in the past 20 years [1] . Latestage (stage III or IV) patients are usually diagnosed with multiple lymph nodes disease involvement or distant metastasis. In most cases, the patients have to receive neck dissection to examine the area of tumor lymphatic drainage and excise the diseased cervical lymph nodes in the lymphatic basin, preventing further disease recurrence.
Historically, patients with unresectable HNSCC have been treated with radiation therapy. Unfortunately, the 5year survival was unsatisfactory and disease recurrence usually occurred within 2 years after the radiation ther apy. For HNSCC patients, there was an impera tive need for a more effective and less invasive regimen after the ablation of the primary tumor. Therefore, concurrent chemoradiotherapy has been readily accepted as a neoadjuvant, as well as an adjuvant therapy for better local and regional control of the disease. Platinumbased chemotherapy administered concomitant with radiation therapy has now become the firstline therapeutic strategy in the clinic due to the radiosensitizing property and cytotoxic efficacy of cisplatin (CDDP) [3] . Several Phase III clini cal trials in locally advanced HNSCC exhibited promising results for CDDP, taxane and 5fluo rouracil threedrug chemotherapy in improving overall survival, particularly for patients with unresectable tumors [4] . However, some clinical trials with CDDP and 5fluorouracil combina tion adjuvant chemotherapy followed by radio therapy showed only minimal improvement in the diseasefree survival and locoregional con trol in comparison with patients who received radiation therapy alone [3] . In addition, most chemotherapeutics, including CDDP, have poor penetration to the lymphatic basin due to its anatomy and monodirectional flow, which lim its their efficacy in treating latestage patients. Herein, we sought to investigate the feasibility of developing a lymphatic drugdelivery system to maximize the efficacy and longterm survival rate of CDDPbased chemotherapy in treating Carrier-based intralymphatic cisplatin chemotherapy for the treatment of metastatic squamous cell carcinoma of the head & neck Background: Since head and neck squamous cell carcinoma (HNSCC) preferentially metastasizes to the locoregional lymphatics, treatment of the tumor-draining cervical lymph nodes is paramount. Results: We developed a hyaluronan-cisplatin (HA-Pt) nanoconjugate with prolonged lymphatic retention and greatly improved tumor tissue deposition for the treatment of metastatic HNSCC. We also developed an orthotopic metastatic xenograft model of HNSCC to examine the efficacy of the nanoconjugate. HNSCC (1/week × 3 weeks) were completely cured for 57% of the female mice in the HA-Pt treatment group, which demonstrated greatly hindered HNSCC progression compared with the standard cisplatin therapy (p < 0.05). Conclusion: With this insight, we will be able to optimize the carriers for better uptake, penetration and retention within cancer cells.
future science group locally advanced HNSCC and to reduce its dosing frequency and the associated length of patient hospital stay.
Experimental
Materials Hyaluronan (HA) from microbial fermentation was purchased from Lifecore Biomedical (MN, USA) as sodium hyaluronate and used without further purification. CDDP was purchased from LC Laboratories (MA, USA). All other reagents were purchased from Fisher Scientific (PA, USA) or SigmaAldrich (MO, USA) and were of American Chemical Society (ACS) grade or better. MilliQ water was used in all experiments. Human HNSCC cell line MDA 1986 was provided by Mark Cohen (University of Kansas Medical Center, KS, USA). Animal procedures were approved by the University of Kansas Institutional Animal Care and Use Committee. Athymic nude mice were purchased from Charles River Laboratories (MA, USA).
Synthesis of HA-Pt conjugates
Cisplatin was conjugated to HA (35,000 g/mol), based on the previously reported procedure [5] . Typically, HA (100 mg) and CDDP (45 mg) were dissolved in ddH 2 O (20 ml) and stirred in the dark for 3 days at ambient temperature (~25°C). The mixture was filtered (0.2 µm nylon membrane) and dialyzed against ddH 2 O (10,000 MWCO; Pierce, IL, USA) for 48 h at 4°C protected from light. Following dialysis, the crude product was concentrated and stored at 4°C. The degree of CDDP substitution was determined by atomic absorption spectroscopy (Varian SpectrAA GTA110 with graphite fur nace). The furnace program was as follows: ramp 25-80°C, hold 2 s, ramp to 120°C, hold 10 s, ramp to 1000°C, hold 5 s, ramp to 2700°C, hold 2 s, cool to 25°C over 20 s. The graphite partition tube was cleaned every 40 samples by baking at 2800°C for 7 s. Argon was used as the injection and carrier gas.
Cell toxicity
The HNSCC cell line MDA1986 was main tained in Dulbecco's modified Eagle medium, supplemented with 10% fetal bovine serum and 1% lglutamine-alanine. Preceding prolifera tion studies, cells were trypsinized and seeded into 96well plates (5000 cells/well). After 24 h, CDDP, HA-Pt or HA was added (n = 12; seven concentrations) and 72 h postaddition, re sazurin blue in 10 µl of phosphatebuffered saline was added to each well (final concen tration of 5 µM). After 4 h, well fluorescence was measured (l ex 560 nm, l em 590 nm) using a f luoro photometer (SpectraMax Gemini; Molecular Devices, CA, USA). IC 50 was deter mined as the midpoint between saline (positive) and cellfree (negative) controls for each plate.
Toxicology analysis
The hearing loss was measured in nude mice after three weekly doses of CDDP intravenous (i.v.) or HA-Pt subcutaneous (s.c.) chemotherapy. Saline was injected via the tail vein into a group of control animals. At the fourth week, a probe was placed inside the external auditory canal of anesthetized mice and an acoustic stimulus was delivered using Smart OAE (Intelligent Hearing Systems, FL, USA). Distortion product oto acoustic emission (DPOAE) was recorded and graphed. Frequencies tested range from 3000 to 32,000 Hz. Amplitude was recorded in dB SPL.
Pathology
Healthy nude mice were randomly divided into three groups and treated with HA-Pt s. at an equivalent dose (3.5 mg/kg). Animals were euthanized 2 weeks after the third treatment was completed. The liver, bilateral kidneys, brain, right (ipsilateral) and left (contra lateral) axillary nodes and underlying tissue at the injection site were excised intact and stored in 80% alcoholic formalin solution overnight for fixation before slide mounting. Mounting using hematoxylin and eosin (H&E) staining were conducted by Veterinary Lab Resources (KS, USA). The pathological examination was performed by a blinded boardcertified veterinarian pathologist (University of Kansas Medical Center).
Tumor model & in vivo imaging
The pCLNRXturbo635 plasmid was con structed by inserting a 715bp AfeI/HindIII fragment of the pTurboFP635C (Evrogen Inc, Moscow, Russia) into a 7675bp AleI/HindIII fragment of the pCLNRX retrovirusexpression vector (Imgenex, CA, USA). The incorporation of the insert was verified by sequencing. Packaging 293GPG cells were used to generate the retrovi ruses, followed by infecting MDA1986 human HNSCC cells and selecting for 2 weeks with 0.8 mg/ml G418. Stable protein production and resulting strong cell nearinfrared cell fluor escence was verified by fluorescence microscopy with a Texas Red filter (data not shown).
Key Terms
Head and neck squamous cell cancer: Cancer that originates from the mucosal cells that line the surface of the upper aerodigestive tract.
Lymphatic metastasis:
Spread of cancer from an organ or tissue to the lymphatic system.
Cancer chemotherapy:
Treatment regimen that is administered to destroy cancer cells using cytotoxic drugs.
Cisplatin: Platinum-based chemotherapeutic for the treatment of a wide spectrum of solid tumors, including head and neck squamous cell cancer and ovarian cancer.
Hyaluronan nanocarrier:
Nanosized drug-delivery vehicles that is made of anionic, biocompatible, and biodegradable polysaccharide hyaluronan.
future science group Stable MDA1986/Turbo635 cells were pre pared in 1 × PBS solution at a cell concentra tion of 10 7 cells/ml. 100 µl of the cell solution was injected under pentobarbital sedation into the oral mucosa layers of nude mice using 27ga needles. Tumor size was measured twice a week by a digital caliper on mice anesthesized with 1.5-2% isoflurane in a 50% oxygen 50% ambi ent air mixture. Tumor volume was calculated using equation 1.
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Before imaging, mice were anesthetized, and HA-Texas Red (10 mg/ml in saline, 100 µl) was injected s.c. over the neck of the animal. The injection area was massaged gently for 5 min and fluorescently imaged over 24 h (CRI Maestro Flex, CRI Inc., MA, USA) using a 445-490 nm filtered halogen excitation light and a 515 nm longpass emission filter. Fluorescence was mea sured in 10 nm bandpass segments from 520 to 720 nm, using a cooled charge coupled device (CCD) camera with autoexposure. Images were spectrally unmixed using the automatic decon volution tools (Maestro version 2.10) to limit skin and intestine autofluorescence resulting from chlorophyll in food.
Treatment
Female nude mice were injected with MDA1986 cells and randomly divided into five groups: saline i.v. group (N = 5), HA s.c. group (N = 6), CDDP i.v. group (N = 5), HA-Pt s.c. group (N = 7), and HA-Pt i.v. group (N = 6). Animals in each group were euthanized once their tumor size reached 1000 mm 3 or 12 weeks after tumor cells were injected. In addition, animals were euthanized during the study if tumors ulcer ated or infections unrelated to tumor growth occured. Facial tumors were observed 2 weeks after tumor cells were implanted. All treat ments were administered 3, 4 and 5 weeks after tumor cell implantation. Three doses of 3.5 mg/kg CDDP, 3.5 mg/kg HA-Pt or physio logical saline were administered i.v. via tail veins; or three doses of 3.5 mg/kg of HA-Pt or HA were administered s.c. around the tumors. The size of the primary tumor was measured weekly. A similar study was conducted using male nude mice, which were treated with either CDDP i. 
Results & discussion
Synthesis & in vitro toxicity of HA-Pt conjugates Efficient conjugation between cis-diammine dichloroplatinum(II) and hyaluronic acid was reported in our previous studies with silver nitrate [6] or without silver nitrate as activating agent (data not shown). CDDP was success fully conjugated to the carboxylate group of hyaluronan (HA) with a substitution degree of approximately 25% w/w. HA-Pt nano conjugates exhibited similar antiproliferative activity as the CDDP in human HNSCC cell line MDA1986 (CDDP IC 50 = 6.6 µM, HA-Pt IC 50 = 6.0 µM) and human oral squamous cell cancer cell line JMAR (CDDP IC 50 = 4.9 µM, HA-Pt IC 50 = 6.1 µM). The in vitro toxicity of the conjugates was due to the toxicity of the slowly released active form of CDDP. Upon cleavage of the ester platinum bond, the released CDDP produces three forms of the hydrolyzed drug: the aqua form (Pt [ [OH] 2 ), which immediately redistribute to reach equilibrium. The active, monohydroxo form of the drug was determined to be the primary species at pH 6.0, based on the calculation using the first and sec ond pK a values for deprotonation (pK a1 5.37 and pK a2 7.21) [7] . The anti proliferative activity of HA-Pt conjugates is likely due to one or both of the following pathways, carriermediated endo cytosis of HA-Pt conjugates, followed by the cleavage of the drug, or drug internalization via passive diffusion or active transport following the release of the drug. Conjugating multiple CDDP molecules to a HA molecule may change the mechanism of drug internalization from pas sive diffusion to carriermediated endocytosis over time, overcoming the likelihood of develop ing early drug resistance due to the presence of membrane efflux pumps.
Uptake of HA-Pt conjugates by MDA1986 cells was confirmed using a fluorescently tagged HA conjugate, which was synthesized by conden sation of Texas Red hydrazide to HA [6] . After 4 h incubation, uptake of HA-Texas Red into the cells was observed using an upright fluores cent microscope. The Texas red bound HA was widely distributed throughout the cytoplasm.
Toxicology analysis
Cisplatin is known to induce dosedependent ototoxicity, leading to mostly irreversible auditory impairment, primarily in the high future science group frequencies, in both human and experimental animals [8, 9] . CDDP is highly plasmaprotein bound after i.v. administration. Approximately 96% of the drug becomes biologically inactive after it binds to the plasma protein, principally serum albumin; whereas the monohydrated fraction of the free drug causes ototoxicity and injuries to the cochlea [9, 10] . CDDP ototoxic ity is likely due to the generation and release of reactive oxygen species postexposure of the mechanosensory hair cells to the active form of the drug [11] . Use of protective antioxidants was demonstrated to attenuate the injuries to the hair cells caused by CDDP chemotherapy due to a free radical scavenging effect [12] [13] [14] .
In this study, mice in both control and treated groups (saline i.v., CDDP i.v. and HA-Pt s.c.) exhibited otoacoustic emission, which indicated that the CDDPtargeted mechanosensory hair cell in the inner ear region remained func tional. However, no systemically significant differences were observed between groups, which is likely due to the relatively low doses (3.5 mg/kg × 3 weeks) that were administered. Zuur et al. reported that lowdose intravenous CDDP chemotherapy caused less acute hearing loss compared with highdose therapy in a study of 60 patients [8] . Studies at a higher dose or more frequent dosing schedule may better reveal the influence of dosing to the degree of ototoxic ity. In 2002, Chen et al. studied the maximum tolerated dose (MTD) of a CDDPloaded bio degradable poly(d,llactidecoglycolide) con jugate, and compared its MTD with the free unbound CDDP [15] . The results revealed that the polymer-drug conjugate had a MTD of 36 mg/kg, exhibiting a onefold increase rela tive to the free CDDP. Thus, an increased dose in our treatment regimen may be expected to induce a noticeable change in the ototoxicity.
Renal toxicity of CDDP is another dose limiting side effect of the anticancer drug. In one of our previous studies, we examined the renal toxicity induced by the free CDDP (i.v., 1.0 and 3.3 mg/kg) or HA-Pt (s.c., formu lation with or without silver, 1.0 and 3.3 mg/kg equivalent CDDP) [16] . The renal toxicity of the drug was monitored by the creatinine level in the urine of the Sprague-Dawley rats for up to 30 days following a single injection. The HA-Pt formulation with silver nitrate as an activating agent was eliminated from the study due to the renal toxicity it caused. The animals that were treated with either HA-Pt silverfree formula tion or unbound CDDP did not demonstrate a statistically significant difference, which is due to the effective functional recovery of the rats following a single dose of the drug, as well as the relatively low dose that was administered. Therefore, we subsequently conducted a kidney pathological study to compare the extent of tis sue degeneration and necrosis of their kidney sections. The results showed that the lymphatic HA-Pt formulation induced milder tissue damage and less renal dysfunction.
Pathology At the conclusion of the 5week toxicity study (weekly dose of 3.5 mg/kg for 3 weeks), ani mals were euthanized and a full pathological examination was performed. Kidney, liver, brain, lymph nodes and underlying tissue of the injection site were normal with no significant microscopic changes for all study groups. This is likely due to the low dosing level adminis tered as well as the reduced drug uptake and accumulation or the upregulated tissue repair. Studies at a higher drug concentration, increased dosing frequency or reduced recovery time at the conclusion of the treatment may result in differentiated CDDP toxicities.
Tumor model & in vivo imaging
In this study, we established an orthotopic murine tumor model of HNSCC by injecting human HNSCC cells -MDA1986 -into the buccal mucosa of nude mice. The model exhib ited rapid and sustained tumor growth, with average survival of up to 12 weeks after tumor cell implantation. The primary tumor proceeded similarly to highly aggressive human HNSCC, invading the mandible and metastasizing to the cervical nodes. To validate the tumor model and verify the incidence of distant metastasis, we intactly removed the primary tumor and the draining lymph nodes from the animal and stored in formalin solution overnight for fixa tion before biopsies. H&E staining tests were conducted and the histology slides showed muscular (middle panel) and glandular (right panel) invasion of the cancer cells into the lymphatics (FiguRe 1) .
In order for our nanocarriers to deliver anti cancer drugs to metastases in the head and neck locoregional lymphatics, carriers should drain from the tumor area to the diseased lymph nodes. We injected HA-Texas Red conjugates to evaluate the drainage into the diseased cervi cal lymph nodes 24 h postinjection (FiguRe 2) . The nanoconjugates slowly diffused from the future science group injection site possibly to the primary tumor and peripheral locoregional lymphatics, which harbor the metastases. If the targeted drain age of the HA conjugates toward the neoplas tic tissue occurred, it is likely to be due to the lympha ngio genesis, leading to the increased accumulation of the nanoconjugates adjacent to the tumor and the cervical lymph nodes. In order to verify the uptake, additional histologi cal evidences for the targeted drainage using a fluorescent microscope will be conducted in our ongoing future experiments. Other polymeric carriers, such as optically labeled dendrimer [17] or dextran [18, 19] , have also been used to enable visualization of the lymphatic drainage.
In order to visualize tumor progression in the early stages, we developed a MDA1986 cell line expressing red fluorescent protein. 
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future science group the active form of the drug, which subsequently drained to the adjacent cervical lymph nodes and the surrounding lymphatic regions. The gradu ally released CDDP did not cause any skin or tissue reaction at the injection site, even though CDDP is well known as a vesicant. This is likely due to the protective effect of HA, which has been used as a rescue medication to alleviate local toxicity effects of chemotherapeutics. A similar tumor suppression effect was also observed by Chen et al. in their treatment efficacy study using a CDDPincorporated polymer conjugate against HNSCC in a chimeric mouse model [15] . Some effect may be due to the increased residence time of CDDP in plasma with the locally injected con jugates. However, this effect would be due to vas cular uptake and subsequent extra vasculation fol lowed by lymphatic uptake in the head and neck region. In another study we recently published, levels in ipsilateral axilla nodes were compared with contralateral, and drug levels in the con tralateral were similar to intravenous levels, with no local 'boost' in even these immediatearea lymphatics with a different drainage basin [16] . Administration of anticancer drugs via poly meric delivery vehicles is a promising method for local delivery of concentrated chemo therapeutics, effectively treating lympha tically metastatic cancers. A study by Dunne et al. revealed that CDDPbound poly(ethylene oxide)block poly(lysine) block copolymer greatly hindered the tumor progression in a squamous cell carcinoma model of the upper aerodigestive tract in ani mals [20] . Another study carried out by Xie et al. reported an enhanced efficacy against laryngeal squamous cell carcinoma in rodents compared with conventional paclitaxel therapy [21] .
Another interesting observation was that the tumor progression of HNSCC exhibited a more aggressive pattern in male nude mice compared with the female animals. All the male animals in the CDDP i.v. group reached an average tumor size of approximately 1000 mm 3 in 2 weeks (FiguRe 4) as opposed to 8 weeks, as observed in the previous female animal studies (FiguRe 3) . On the other hand, 80% of the male animals in the HA-Pt s.c. group developed tumors of approxi mately 1000 mm 3 in 3 weeks and 20% of the animals were able to live through the end of the fourth week (FiguRe 4) . Therefore, gender differ ences, as well as weight loss and stress, may be contributing factors that are responsible for the differentiated carcinoma progression. In addi tion, gender differences in the pharmaco kinetics and tolerability of CDDP may also impact the differences in survival. Stakisaitis et al. found in rats that CDDPrelated hypo natermia and renal toxicity is more pronounced in males than females, although the mechanism is not understood [22] . In human studies, tobacco and alcohol consumption were believed to be the major, but not the only, factors inducing the occurrence and recurrence of HNSCC. Other factors, such as age, weight loss, nutritional status and complications may also play a role in the survival of patients [23] . Dahlstrom et al. conducted a demographic study of 172 never smoker-never drinker patients, describing the age and sex distribution of HNSCC patients, and identifying the specific types of most com monly diagnosed HNSCC [24] . A similar study was also performed by Onyango et al., showing an overall male preponderance in the occurrence of HNSCC among 793 patience [25] . Additional factors affecting the disease progression and metastasis are still under investigation.
Conclusion
This study demonstrates that intralymphatic delivery of CDDP may be a promising treat ment regimen to deliver chemotherapeutics to the primary malignancy, locoregional lym phatics and metastases, with greatly improved in vivo efficacy and survival compared with conventional CDDP chemotherapy. Successful completion of this study may provide a plat form for the development of other polymeric drugdelivery models for the treatment of a wide spectrum of lymphatically metastatic cancers. The platinumbased HA conjugates can either be administered as a neoadjuvant therapy prior to surgery to reduce tumor size and control cancer progression, or given as an adjuvant therapy postsurgery to reduce the risk of recurrence and eradicate cancer residu als, such as micrometastases. In addition, due to the sustained release characteristics of the conjugate, weekly or biweekly HA-Pt injections could replace the conventional daily infusion, leading to improved patient compliance and reduced healthcare cost.
Future perspective
Despite major strides in cancer prevention and treatment during recent decades, there has been only a modest improvement in overall survival. Over half of HNSCC patients will face recur rence at some point, and these cancers recur because current imaging tools fail to detect occult disease or therapies fail to completely eradicate resistant disease. More frequent and intense radioimaging or stronger regimens of chemotherapy and radiation would be detri mental in the long run to patients' health and, therefore, new approaches are needed. Localized therapies stand a stronger chance of eradicating residual disease since higher doses of chemotherapy can be administered without doselimiting toxicity to the heart, kidneys and liver. Localized chemotherapy is already used to great success in the treament of peritoneal disease in colon cancer using heated intraperitoneal chemotherapy, limb melano mas with heated isolated limb perfusions and liver cancer using isolated limb perfusions. However, there is no way to isolate most organs and tissues for concentrated chemotherapy, such as the breasts, neck and lungs. For most tissues, the lymphatics are an ideal pathway for local therapy due to their importance in early cancer metastasis. Localized chemo therapy may become an important component future science group in the treatment of earlystage cancers that are still confined to the primary tumor and local lymphatics; yet, to date, there are no tools in the clinic to localize chemotherapy in the lymph system.
Localized delivery systems such as we have described can effectively treat these earlystage diseases and we believe they will represent a new treatment option in the next 5-10 years. Next generation systems will incorporate both imag ing and diagnostic capabilities in the drug or drug carriers, so that the staging (or re staging) of the disease can be followed immediately by treatment to reduce treatment costs, limit the need for invasive surgeries and intravenous treatments and increase the likelihood that all disease can be eliminated in the early, more controllable stages.
